Adhera Therapeutics Valuation
| ATRXDelisted Stock | USD 0.72 0.00 0.00% |
Adhera Therapeutics is overvalued. Adhera Therapeutics shows a prevailing Real Value of $0.6 per share. The current price of the firm is $0.72. Our model approximates the value of Adhera Therapeutics from analyzing the firm fundamentals such as return on asset of -4.48, and Shares Outstanding of 3.16 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Adhera Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Adhera Therapeutics is based on 3 months time horizon. Increasing Adhera Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Adhera Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Adhera Pink Sheet. However, Adhera Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.72 | Real 0.6 | Hype 0.72 |
The intrinsic value of Adhera Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Adhera Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Adhera Therapeutics helps investors to forecast how Adhera pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adhera Therapeutics more accurately as focusing exclusively on Adhera Therapeutics' fundamentals will not take into account other important factors: Adhera Therapeutics Total Value Analysis
Adhera Therapeutics is presently projected to have valuation of 10.55 M with market capitalization of 2.18 M, debt of 7.35 M, and cash on hands of 849 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Adhera Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.55 M | 2.18 M | 7.35 M | 849 K |
Adhera Therapeutics Asset Utilization
One of the ways to look at asset utilization of Adhera is to check how much profit was generated for every dollar of assets it reports. Adhera Therapeutics shows a negative utilization of assets of -4.48 percent, losing $0.0448 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Adhera Therapeutics shows how unproductive it operates for each dollar spent on its assets.Adhera Therapeutics Ownership Allocation
Adhera Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Adhera Therapeutics Profitability Analysis
Net Loss for the year was (6.35 M) with loss before overhead, payroll, taxes, and interest of (157 K).About Adhera Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Adhera Therapeutics. We calculate exposure to Adhera Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adhera Therapeutics's related companies.Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana. Adhera Therapeutics is traded on OTC Exchange in the United States.
8 Steps to conduct Adhera Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Adhera Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Adhera Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Adhera Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Adhera Therapeutics' revenue streams: Identify Adhera Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Adhera Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Adhera Therapeutics' growth potential: Evaluate Adhera Therapeutics' management, business model, and growth potential.
- Determine Adhera Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Adhera Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Adhera Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 17 M | |
| Retained Earnings | -53 M | |
| Shares Float | 2.3 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Adhera Pink Sheet
If you are still planning to invest in Adhera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adhera Therapeutics' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |